GRI Bio (GRI) Competitors

$2.15 -0.11 (-4.87%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$2.15 +0.00 (+0.05%)

As of 07:00 AM Eastern

GRI vs. MBRX, CLRB, BLRX, AIMD, and HOTH

Should you buy GRI Bio stock or one of its competitors? MarketBeat compares GRI Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GRI Bio include Moleculin Biotech (MBRX), Cellectar Biosciences (CLRB), BioLineRx (BLRX), Ainos (AIMD), and Hoth Therapeutics (HOTH). These companies are all part of the "pharmaceutical products" industry.

How does GRI Bio compare to Moleculin Biotech?

GRI Bio (NASDAQ:GRI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

In the previous week, Moleculin Biotech had 2 more articles in the media than GRI Bio. MarketBeat recorded 7 mentions for Moleculin Biotech and 5 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.98 beat Moleculin Biotech's score of 0.12 indicating that GRI Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moleculin Biotech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GRI Bio currently has a consensus target price of $1,008.00, suggesting a potential upside of 46,783.72%. Moleculin Biotech has a consensus target price of $22.00, suggesting a potential upside of 900.00%. Given GRI Bio's higher probable upside, equities analysts clearly believe GRI Bio is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Moleculin Biotech is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$235.02	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$32.75	N/A

Moleculin Biotech's return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-289.01%	-171.12%
Moleculin Biotech	N/A	N/A	-60.88%

GRI Bio has a beta of -1.22, indicating that its share price is 222% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

GRI Bio beats Moleculin Biotech on 6 of the 11 factors compared between the two stocks.

How does GRI Bio compare to Cellectar Biosciences?

GRI Bio (NASDAQ:GRI) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GRI Bio currently has a consensus target price of $1,008.00, suggesting a potential upside of 46,783.72%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 243.75%. Given GRI Bio's higher probable upside, equities analysts clearly believe GRI Bio is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cellectar Biosciences is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$235.02	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A

GRI Bio's return on equity of -289.01% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-289.01%	-171.12%
Cellectar Biosciences	N/A	-298.05%	-144.59%

GRI Bio has a beta of -1.22, indicating that its share price is 222% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 9 more articles in the media than GRI Bio. MarketBeat recorded 14 mentions for Cellectar Biosciences and 5 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.98 beat Cellectar Biosciences' score of 0.78 indicating that GRI Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GRI Bio beats Cellectar Biosciences on 7 of the 11 factors compared between the two stocks.

How does GRI Bio compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 8.7% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GRI Bio has a consensus target price of $1,008.00, suggesting a potential upside of 46,783.72%. Given GRI Bio's higher possible upside, analysts clearly believe GRI Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

BioLineRx has higher revenue and earnings than GRI Bio. BioLineRx is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.28	-$1.17M	-$0.17	N/A
GRI Bio	N/A	N/A	-$11.96M	-$235.02	N/A

GRI Bio has a net margin of 0.00% compared to BioLineRx's net margin of -99.58%. BioLineRx's return on equity of -5.61% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-99.58%	-5.61%	-2.81%
GRI Bio	N/A	-289.01%	-171.12%

BioLineRx has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.22, indicating that its stock price is 222% less volatile than the broader market.

In the previous week, GRI Bio had 3 more articles in the media than BioLineRx. MarketBeat recorded 5 mentions for GRI Bio and 2 mentions for BioLineRx. GRI Bio's average media sentiment score of 0.98 beat BioLineRx's score of 0.93 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLineRx and GRI Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does GRI Bio compare to Ainos?

Ainos (NASDAQ:AIMD) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, Ainos and Ainos both had 5 articles in the media. GRI Bio's average media sentiment score of 0.98 beat Ainos' score of 0.08 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ainos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRI Bio has lower revenue, but higher earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	105.42	-$14.77M	-$2.89	N/A
GRI Bio	N/A	N/A	-$11.96M	-$235.02	N/A

GRI Bio has a consensus target price of $1,008.00, suggesting a potential upside of 46,783.72%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

34.0% of GRI Bio shares are owned by institutional investors. 9.8% of Ainos shares are owned by company insiders. Comparatively, 8.7% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GRI Bio has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -144.01% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-144.01%	-62.00%
GRI Bio	N/A	-289.01%	-171.12%

Ainos has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.22, indicating that its stock price is 222% less volatile than the broader market.

Summary

GRI Bio beats Ainos on 8 of the 14 factors compared between the two stocks.

How does GRI Bio compare to Hoth Therapeutics?

Hoth Therapeutics (NASDAQ:HOTH) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

In the previous week, GRI Bio had 3 more articles in the media than Hoth Therapeutics. MarketBeat recorded 5 mentions for GRI Bio and 2 mentions for Hoth Therapeutics. Hoth Therapeutics' average media sentiment score of 1.43 beat GRI Bio's score of 0.98 indicating that Hoth Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Hoth Therapeutics	Positive
GRI Bio	Positive

Hoth Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.90	N/A
GRI Bio	N/A	N/A	-$11.96M	-$235.02	N/A

Hoth Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 650.86%. GRI Bio has a consensus price target of $1,008.00, suggesting a potential upside of 46,783.72%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Hoth Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 6.9% of Hoth Therapeutics shares are owned by insiders. Comparatively, 8.7% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Hoth Therapeutics' return on equity of -139.84% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hoth Therapeutics	N/A	-139.84%	-126.88%
GRI Bio	N/A	-289.01%	-171.12%

Hoth Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.22, indicating that its share price is 222% less volatile than the broader market.

Summary

GRI Bio beats Hoth Therapeutics on 8 of the 13 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRI vs. The Competition

Export

Metric	GRI Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.27M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.01	18.47	20.66	25.63
Price / Sales	N/A	294.84	547.76	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.52	6.93	9.88	6.97
Net Income	-$11.96M	$24.11M	$3.55B	$333.62M
7 Day Performance	-3.37%	5.89%	1.69%	1.09%
1 Month Performance	-12.96%	-0.91%	0.48%	3.08%
1 Year Performance	-94.70%	74.58%	39.39%	35.68%

GRI Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRI GRI Bio	2.6266 of 5 stars	$2.15 -4.9%	$1,008.00 +46,783.7%	-94.8%	$3.27M	N/A	N/A	1	News Coverage Earnings Report Upcoming Earnings Gap Up
MBRX Moleculin Biotech	2.8199 of 5 stars	$2.34 -4.1%	$22.00 +840.2%	-91.1%	$13.02M	N/A	N/A	20	Earnings Report Gap Up
CLRB Cellectar Biosciences	4.4035 of 5 stars	$2.92 -4.6%	$11.00 +276.7%	-55.7%	$12.98M	N/A	N/A	10	News Coverage Earnings Report Gap Down
BLRX BioLineRx	1.0843 of 5 stars	$3.11 +4.4%	N/A	-1.0%	$12.97M	$1.18M	N/A	40
AIMD Ainos	1.0669 of 5 stars	$1.68 -3.4%	N/A	-34.2%	$12.64M	$120K	N/A	40	News Coverage Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRI) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRI Bio (GRI) Competitors

GRI vs. MBRX, CLRB, BLRX, AIMD, and HOTH

How does GRI Bio compare to Moleculin Biotech?

Summary

How does GRI Bio compare to Cellectar Biosciences?

Summary

How does GRI Bio compare to BioLineRx?

Summary

How does GRI Bio compare to Ainos?

Summary

How does GRI Bio compare to Hoth Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRI Bio (GRI) Competitors

GRI vs. MBRX, CLRB, BLRX, AIMD, and HOTH

How does GRI Bio compare to Moleculin Biotech?

Does the media refer more to GRI or MBRX?

Do analysts recommend GRI or MBRX?

Which has stronger valuation & earnings, GRI or MBRX?

Is GRI or MBRX more profitable?

Which has more volatility & risk, GRI or MBRX?

Do insiders and institutionals have more ownership in GRI or MBRX?

Summary

How does GRI Bio compare to Cellectar Biosciences?

Do insiders and institutionals have more ownership in GRI or CLRB?

Do analysts recommend GRI or CLRB?

Which has stronger valuation & earnings, GRI or CLRB?

Is GRI or CLRB more profitable?

Which has more volatility & risk, GRI or CLRB?

Does the media refer more to GRI or CLRB?

Summary

How does GRI Bio compare to BioLineRx?

Do insiders & institutionals hold more shares of BLRX or GRI?

Do analysts rate BLRX or GRI?

Which has stronger valuation & earnings, BLRX or GRI?

Is BLRX or GRI more profitable?

Which has more volatility & risk, BLRX or GRI?

Does the media prefer BLRX or GRI?

Summary

How does GRI Bio compare to Ainos?

Does the media prefer AIMD or GRI?

Which has stronger valuation & earnings, AIMD or GRI?

Do analysts rate AIMD or GRI?

Do insiders & institutionals hold more shares of AIMD or GRI?

Is AIMD or GRI more profitable?

Which has more volatility & risk, AIMD or GRI?

Summary

How does GRI Bio compare to Hoth Therapeutics?

Does the media favor HOTH or GRI?

Which has higher earnings & valuation, HOTH or GRI?

Do analysts rate HOTH or GRI?

Do insiders & institutionals hold more shares of HOTH or GRI?

Is HOTH or GRI more profitable?

Which has more risk & volatility, HOTH or GRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools